Welcome to our dedicated page for Prelude Therapeutics news (Ticker: PRLD), a resource for investors and traders seeking the latest updates and insights on Prelude Therapeutics stock.
Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a clinical-stage precision oncology company, and its news flow reflects the progress and risks of early-stage cancer drug development. Company announcements frequently cover updates on highly selective SMARCA2 degraders, oral KAT6A degraders, a mutant selective JAK2V617F JH2 inhibitor program for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Investors and researchers following PRLD news can expect regular reports on clinical trial milestones, such as Phase 1 dose-escalation progress for PRT7732, completion of Phase 1 studies for PRT3789, and plans for Phase 2 combinations with agents like pembrolizumab. Press releases also summarize preclinical data presented at major medical meetings, including the American Association for Cancer Research, the American Society of Hematology, European Hematology Association, and other oncology-focused conferences.
Prelude’s news often highlights strategic portfolio decisions, for example prioritizing KAT6A and JAK2V617F programs, pausing further clinical development of certain SMARCA2 programs, and expanding collaborations. Announcements have detailed an exclusive option agreement with Incyte for the JAK2V617F program and an expanded collaboration with AbCellera Biologics around degrader payloads for precision DACs.
In addition, PRLD news includes quarterly financial results, cash runway commentary, and governance updates such as board appointments and leadership changes. For those tracking precision oncology and targeted protein degradation, this news stream provides insight into Prelude’s evolving pipeline, partnership activity, and regulatory and listing developments. Bookmark this page to review the latest earnings releases, scientific data disclosures, and corporate updates related to Prelude Therapeutics stock.
Prelude Therapeutics (Nasdaq: PRLD) presented preclinical data at ASH 2025 for two myeloproliferative neoplasm (MPN) programs: a JAK2V617F-selective JH2 inhibitor (PRT12396) and mCALR-targeted degrader antibody conjugates (DACs) carrying a CDK9 degrader payload.
Key points: PRT12396 selectively inhibited JAK2V617F while preserving wild-type JAK2 signaling, showed superior preclinical activity versus ruxolitinib, completed GLP toxicology, and the company anticipates an IND filing and phase 1 start in Q1 2026. The JAK2 program is subject to an exclusive option agreement with Incyte announced November 2025. The mCALR x CDK9 DACs delivered mutant-selective CDK9 degradation, demonstrated deep mutant-selective killing in vitro and in vivo, and spared healthy hematopoietic cells, supporting disease‑modifying potential.
Prelude Therapeutics (Nasdaq: PRLD) reported Q3 2025 results and a pipeline update on November 12, 2025. The company reported cash, cash equivalents, restricted cash and marketable securities of $58.2M at September 30, 2025 and said it received subsequent license and collaboration payments including $60M from Incyte in November 2025, with management estimating a cash runway into 2027. Q3 revenue rose to $6.5M versus $3.0M a year earlier; R&D expense fell to $21.7M and G&A to $5.2M. Net loss narrowed to $19.7M, $0.26 per share. Key programs: JAK2V617F JH2 inhibitor IND expected H1 2026 and KAT6A oral degrader IND expected mid-2026; multiple preclinical abstracts accepted at ASH 2025.
Prelude Therapeutics (NASDAQ: PRLD) announced an exclusive option agreement with Incyte on a previously undisclosed JAK2V617F mutant selective JH2 inhibitor, prioritized its KAT6A selective degrader program for ER+ breast cancer, and paused its SMARCA2 degrader clinical development.
The Incyte deal includes an upfront payment of $35M, a $25M equity investment, and up to $100M if the option is exercised; Prelude retains program ownership until exercise. As of Oct 31, 2025 Prelude had ~$52M cash and will receive $60M at close; cash runway is expected into 2027 or potentially into Q3 2028 if Incyte exercises the option. Prelude will report Q3 2025 results and hold a call on Nov 12, 2025.
Prelude Therapeutics (NASDAQ:PRLD) announced an exclusive option agreement with Incyte (NASDAQ:INCY) for Prelude’s mutant selective JAK2V617F JH2 inhibitor program for myeloproliferative neoplasms (MPNs).
Prelude will receive $60 million in capital at close ($35M upfront plus $25M strategic equity via 6.25M shares at $4.00), an option purchase price of $100 million, and up to $775 million in milestones plus royalties, for combined potential cash of $910 million excluding royalties. Prelude retains program rights if Incyte declines the option. Program data accepted for an oral ASH presentation Dec 6-9, 2025.
Prelude Therapeutics (Nasdaq: PRLD) announced publication of two abstracts accepted for oral presentation at the ASH 67th Annual Meeting, December 6-9, 2025 in Orlando.
The abstracts report preclinical data for two discovery programs: orally bioavailable JAK2V617F JH2 mutant-selective inhibitors showing mutant-specific inhibition, normalization of blood counts and spleen size in JAK2VF mouse models and selective reduction of JAK2VF progenitors; and mCALR-targeted DACs delivering a CDK9 degrader that selectively eliminates CALR-mutant MPN progenitors while sparing healthy CD34+ cells.
Prelude Therapeutics (Nasdaq: PRLD) announced that Katina Dorton, J.D., MBA was appointed to its Board of Directors effective October 17, 2025.
Ms. Dorton brings >30 years of healthcare and life‑sciences experience, including senior finance roles, investment banking, service as CFO at NodThera, and having raised $82 million in crossover funding while at Repare Therapeutics. She will succeed Mardi C. Dier, who is resigning from the board effective October 17, 2025, and Ms. Dorton will assume the role of Audit Committee chair.
Prelude Therapeutics (Nasdaq: PRLD) reported Q2 2025 financial results and provided updates on its clinical pipeline. The company's oral SMARCA2 degrader PRT7732 is currently enrolling its seventh dosing cohort at 125mg, with preliminary data expected by year-end 2025. Prelude has completed Phase 1 study of PRT3789, its IV SMARCA2 degrader, but decided to pause its development to focus resources on PRT7732.
The company reported $77.3 million in cash and equivalents as of June 30, 2025, providing runway into Q2 2026. Q2 net loss was $31.2 million ($0.41 per share), improved from $34.7 million ($0.46 per share) in Q2 2024. The company remains on track to file an IND for its oral KAT6A degrader program in H1 2026.
FAQ
What is the current stock price of Prelude Therapeutics (PRLD)?
What is the market cap of Prelude Therapeutics (PRLD)?
